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In silico models of signal transduction pathways have been successful both qualitatively as well
as quantitatively in describing how complex protein networks control cell function. Moreover,
the study of networks has been used to elucidate not only how these pathways control the com-
plex regulation and response mechanism of cells, but also provide insight into how a breakdown
in the biological circuitry can lead to particular disease states.
We have recently examined the circuitry within the MAPK signal transduction pathway to un-
derstand how changes within this canonical network may lead to malfunction, notably the rise
of proto-oncogenic cells. In addition we have developed a new complementary technique that
provides insight into which key players within the pathway are most likely to be most conducive
to selective inhibition within this transformed line of cells. These tools have been made freely
available to the public, as part of a software suite developed by our group, Cellsim1 . I will give
an overview on how Cellsim may be used to quantitate cell function and moreover malfunction.
1 Introduction
Computational Biophysics has always played a complementary role to the experimental
biological sciences. The role of a computational biophysicist, as such, is not to develop
tools that simply reassure the experimentalists that well-regarded experiments may, in fact,
be duplicated in silico, but instead must also provide new predictive and quantitative tools
that provide new insight into biological mechanism or function. New tools from the devel-
opment of new experimentally designed united force fields such as UNRES2 to new special
purpose hardware techniques such as MDGRAPE3 have given rise to new predictive math-
ematical and computational methods that can probe behavior of individual proteins on a
femtosecond scale. It is in this sense that new tools such as systems biology have been
developed to address the complementary issue of how these proteins can act en masse to
dictate not only form, but intra-cellular behavior4–8. The scale is perhaps different (from
angstrom to micrometer, from individual proteins to micromolar concentrations, from pi-
cosecond to millisecond and so forth), but the philosophy is the same. The method of
systems biology is to take experimental data that is relatively simple to reproduce, and to
use it to provide insight into phenomena that can not be easily elucidated by an existing set
of experiments.
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Systems biology uses these experimentally derived, computational techniques to elu-
cidate both how cells have the ability to respond to external stimuli and how intra-cellular
signaling circuitry that is essential for cell function is controlled. The mechanism by which
this occurs depends fundamentally on the way in which cells use protein networks as the
mechanism for translating extra-cellular signals into intra-cellular behavior. Hence, the
complexity of signal transduction networks is based on the interplay between different as-
pects of the signaling process, any of which may change with subtle external or internal
changes to the cell9. The focus of our group is on one particularly important signaling
cascade: the MAPK signal transduction pathway.
2 The Canonical MAPK Signal Transduction Pathway
The canonical MAPK signaling cascade (Figure 1) is perhaps one of the most well stud-
ied signal cascades, both experimentally and computationally10. This central cascade is
critical for governing cell growth and proliferation as well as actin cytoskeleton rear-
rangement11–14. Stimulation of the cascade activates many downstream effectors including
PI3K15, Bcl-216, and PKC,17, 18 among others10. The central cascade is activated via the
following mechanism: The epidermal growth factor (EGF) signaling begins with the epi-
dermal growth factor receptor (EGFR) and traverses a series of signaling proteins to the Ras
protein. The Ras protein works in part by activating a series of kinases starting from Raf
(a Mitogen Activated Protein Kinase Kinase Kinase (MAPKKK) ) which activates the Mi-
togen Activated Protein ERK Kinase (MEK), This in turn activates the extracellular-signal
regulation kinase (ERK), which subsequently translocates to the nucleus and stimulates
a series of growth promoting transcription factors19. The pathways described represent a
simplified description of the full process of cell signaling, as this cascade is but a single
member of a complex set of parallel, interacting pathways9.
2.1 Oncogenic Transformation of the MAPK Pxathway
The central member of the MAPK pathway, Ras, illustrates the importance of transforma-
tions within the MAPK signal transduction cascade. The Ras protein is a GTP-binding
signaling protein, activating downstream effectors by binding to GTP, while inactive in the
GDP bound form. The Ras oncogene was first found experimentally by its ability to in-
duce tumor-like growth in fibroblasts20–22. The major oncogenic transformation involves
specific mutations in Ras that prevent hydrolysis of GTP-bound Ras by GTPase Activating
Proteins (GAP), leaving Ras continuously activated (and thus persistently signaling down-
stream effectors). These particular mutations have been implicated in approximately 30%
of all human cancers, predominantly in lung, colon and pancreatic cancers23. This is likely
an under-estimation of oncogenic transformation of Ras related cascades as mutations in
other effectors downstream may cause a similar transformation in absence of mutations in
the Ras gene itself. The transformation to tumor cells does not occur by a mutational event
in Ras alone, but through a series of malignant transformations along or between several
distinct pathway species24.
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Figure 1. The canonical MAPK pathway
3 Methods
Systems biology methods developed by our group use either ordinary differential equations
(ODEs) or partial differential equations (PDEs) to describe the overall temporal or spatio-
temporal behavior of the protein network within (and between) compartments of a cell7, 8.
Enzymatic reactions and other chemical interactions are represented as simply a system of
ODEs which couple to active and passive transport. Passive transport includes processes
such as simple diffusive processes. Active transport includes explicit advective terms,
modeling for instance transport along actin filaments and other ATP driven processes.
Elementary chemical reactions describe the enzymatic and non-enzymatic reactions
within each compartment. These reactions may be written as:
∑
i
niRi
kf−⇀↽−
kb
∑
j
njPj (1)
where a set of reactant species Ri with stoichiometric coefficients ni inter-converts into
a set of product species Pj with stoichiometric coefficients nj with rate constants kf and
kb. As collisions that are greater than bimolecular are rare, the order of an elementary
chemical reaction is not typically greater than 2. Characteristic of signaling pathways are
enzymatic reactions such as phosphorylation or dephosphorylation events. These reactions
may be expressed as a combination of a reversible and an irreversible chemical reaction as
follows:
E + S
k1−⇀↽−
k2
E.S
k3−→ E + S∗ (2)
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where E represents an enzyme which catalyzes the substrate S. The intermediate species
E.S first forms reversibly with rate constants k1 and k2 followed by an irreversible cat-
alytic step with rate constant k3 which releases the activated substrate S∗ and the enzyme
for further catalysis.
These reactions lead to a set of ordinary differential equations such that one may ex-
press the time rate of change in concentration of all species as a system of unimolecular
and bimolecular reactions such that:
d[Ci]
dt
=
∑
j
kij [Cj ] +
∑
l>m
kilm[Cl][Cm] +
∑
j
T (Ci, Cj) (3)
where kij is the rate constant for a unimolecular reaction involving species Ci and Cj
at concentrations [Ci] and [Cj ] respectively. If kilm is positive then kilm represents the
rate constant of formation of species Ci from a bimolecular reaction between species Cl
and Cm with concentrations [Cl] and [Cm]. Conversely, if kilm is negative then kilm
represents the rate constant of disassociation of species Ci into two species Cl and Cm.
T (Ci, Cj) represents a function governing the passive transport of a species Ci into a
different compartment at which time it is labeled with a subscript j as Cj via passive
channels.
3.1 Mutations
A mutation in a particular gene in a signaling pathway manifests itself in one of two ways.
In the first case, the mutation may directly affect the interaction between two species. If
two species A and B reversibly associate/disassociate with rate constants kf/kb:
A+B
kf−⇀↽−
kb
A.B (4)
then a mutation of this type will perturb kf or kb by some amount. For instance, lowering
kf by some amount represents a mutation that hinders the ability of species A or B to
associate into A.B. We define a mutation of this type as an “interaction” mutation. This
mutation may occur in either species A or B, as the effect is the same. A simple analysis
using Arrhenius theory may be used to connect the free energy change from a mutation
with the corresponding kinetic parameters kf and kb6, 5.
The rate of interconversion from reactant to product may be given as:
kf = Ae
−Ea/kBT (5)
where A is a constant prefactor, Ea is the barrier energy of activation and kB is Boltz-
mann’s constant. Mutations in the enzyme may affect a transition rate by either increasing
the barrier height or changing the free energy of the initial state of the system by some
amount ∆E. The new mutated system may therefore be considered to be a perturbed sys-
tem with a new barrier of height E′a and a forward transition rate of k′f (Figure 2). The
ratio k′f/kf is :
k′f/kf =
e−(Ea+∆E)/kbT
e−Ea/kbT
(6)
and simplifying
k′f/kf = e
−∆E/kbT (7)
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Figure 2. Graphical representation of the energy barriers involved in a reaction. An increase in the barrier height
lowers the rate constant. The lower rate constant k′f corresponds to the greater barrier height E
′
a.
The right side of eq. (7) is a function of the change in the barrier height and not of the
barrier height Ea itself.
Eq. 7 can be used to simulate the effect of any single mutation on the normal MAPK
signal transduction pathway without having to explicitly dileanate the underlying cause.
The key effect governing the transformation of the normal MAPK signal transduction path-
way, is the ability to activate downstream ERK without EGF stimulation. The results from
this analysis will be published in a forthcoming manuscript25.
Moreover, such mutations may be rank ordered in terms of ∆E. The top 10 mutations
(those that need the smallest ∆E increase to activate ERK ) are shown in table 1.
Rank kmod Reaction Dir
1 0.75 X* + PP2A⇋ X*-PP2A f
2 0.75 X*-PP2A → PP2A +X f
3 0.6 Raf* +GTP-Ras⇋ Raf-GTP-Ras* b
4 0.55 Raf* + PP2A⇋ Raf*-PP2A f
5 0.55 GTP-Ras + GAP⇋ GTP-Ras-GAP f
6 0.55 GTP-Ras-GAP → GAP +GDP-Ras f
7 0.55 AA → APC f
8 0.55 Ca-Capump → Capump +Caext f
9 0.5 X + Raf-GTP-Ras*⇋ X-Raf-GTP-Ras* b
10 0.5 Ca + Capump ⇋ Ca-Capump f
Table 1. Ranking of the ‘interaction” mutations based on the highest value of kmod below which ERK activation
occurs. These reactions represent the “inhibiting” set of mutations. Reactions with X (or X*) or (g) represent
group reactions.
4 Drug Targeting
With drug development costs now reaching 500 million dollars and more, development
strategies represent a significant hurdle in bringing new therapeutics to the marketplace26.
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The experimental development cycle can be optimized in a manner that minimizes the
number of false positives during costly clinical trials using systems biology techniques
similar to those described previously in this manuscript to detect proto-oncogenes. Rather
than modeling the effect of a mutation, modeling of an inhibitor may be performed with
the addition of a single chemical reaction representing simple competitive binding between
the substrate and the target protein:
I + S
kb−⇀↽−
kf
I.S (8)
The binding free energy can be calculated from the equilibrium constant keq of the
reversible binding reaction. A particular inhibitor may bind to any substrate within the
MAPK pathway. The efficacy of the inhibitor against a particular target is gauged by its
ability to stop auto-activation of the pathway of the entire set of transformed cells described
in the previous section. Furthermore, targets that successfully inhibit all transformed cell
lines are further ranked by the minimum binding affinity and concentration needed to de-
activate all cell lines.
5 Concluding Remarks
Computational biophysics has been successful in underscoring how quantitation and sim-
ulation can be used to address difficult problems of interest in biology, as evidenced by
the many articles within this book. Systems biology continues this tradition with an em-
phasis on the macroscopic rather than the microscopic, focusing on not single molecules
or proteins but rather how entire systems interact. As illustrated, systems biology can be
used to not only quantitate how behavior is governed, but moreover how malfunctions in
the signaling process can give rise to aberrant signaling processes. Finally, an analysis of
these aberrant networks can be used to suggest novel treatment strategies.
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